IM Cannabis Reports Strong Profit Growth Amid Challenges

Im Cannabis Corp ( (IMCC) ) has released its Q2 earnings. Here is a breakdown of the information Im Cannabis Corp presented to its investors.

IM Cannabis Corp. is an international medical cannabis company that provides premium cannabis products to medical patients in Israel and Germany, leveraging a data-driven approach and a globally sourced product supply chain. In its second quarter of 2025, IM Cannabis reported a strong increase in gross profit and margin growth despite a 14% decline in revenue due to external challenges such as the ongoing conflict in Israel and supply chain delays. Key financial highlights include a 306% increase in gross profit to $3.4 million and a 371% increase in gross margin to 27%. The company also achieved an EBITDA profit of $0.1 million, a significant improvement from a loss of $2.3 million in the same quarter last year. Operating expenses remained stable with a slight increase of 2%. Looking ahead, IM Cannabis management remains optimistic about recovering the revenue impact in the coming quarters and is focused on sustainable, profitable growth as market conditions normalize.